Figure 1.1 The figure illustrates the process of restenosis after bare stent

More recently, however, drug-eluting stents have emerged as an effective therapeutic option to reduce the incidence of in-stent restenosis. The sirolimuseluting stent was the first of such devices with proven capacity to decrease neointimal growth and ultimately reduce late restenosis. The present chapter will focus on describing the device structure, pre-clinical background, and the clinical information currently available from early studies and randomized trials conducted to date with the sirolimus-eluting stent.